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acute vulvovaginitis. Only two patients presented hematuria 
in the follow-up, one documented to be radiation-induced, 
and the second was a superficial tumor relapse. 
Conclusions: Radiochemotherapy after TURB for invasive 
bladder cancer in very elderly patients with good general 
condition, is well tolerated and offers good 3-year overall 
survival rates. The high rates of locally complete response in 
these patients, makes RCT as an appropriate therapeutic 
option. The optimal schedule of concurrent chemotherapy 
needs to be ascertained. 
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Purpose/Objective: To identify changes in presentation, 
treatment and outcomes of older patients with low-grade 
glioma (LGG) over the past 50 years. 
Materials and Methods: Records of adults aged 55 or older 
upon diagnosis at Mayo Clinic between 1960 and 2011 with 
WHO grade II LGG were reviewed. They were grouped by 
those diagnosed before (group I: 1960-1989) and after (group 
II: 1990-2011) the routine use of post-operative MRI. 
Results: Of the 852 adults diagnosed with LGG in our 
database, 94 were aged 55 or older. Median follow-up was 
11.4 years. Pathologic diagnoses included astrocytoma in 
55.3%, mixed oligoastrocytoma in 18% and oligodendroglioma 
in 26.7%. Gross total resection (GTR) was achieved in 9.6%, 
radical subtotal resection (rSTR) in 6.4%, subtotal resection 
(STR) in 20.2% and biopsy only in 63.8%. More patients in the 
modern era received GTR/rSTR (19.7% versus 7.1%), though 
the difference was not statistically significant. Median 
progression-free survival (PFS) was 3.0 years, with 5- and 10-
year PFS rates of 31% and 10%, respectively. Median, 5- and 
10-year overall survival (OS) was 4.1 years, 43% and 17%, 
respectively. PFS and OS were not statistically significantly 
different in group II compared with group I. Factors 
associated with PFS on univariate analysis included 
sensory/motor symptoms, astrocytoma histology, contrast 
enhancement and GTR/rSTR. Factors associated with OS on 
univariate analysis included astrocytoma histology, deep 
location, contrast enhancement, GTR/rSTR and PORT. On 
multivariate analysis, astrocytoma histology, contrast 
enhancement and GTR/rSTR remained statistically 
significantly associated with PFS. On multivariate analysis for 
OS, astrocytoma histology, deep location, contrast 
enhancement and GTR/rSTR remained statistically 
significant.  
Conclusions: This retrospective series of older adults with 
LGG confirms the poor prognosis of patients with these 
tumors. Despite reports of improving in outcomes for younger 
patients treated in the modern era, outcomes have not 
significantly improved for older patients. If medically safe, 
strong consideration should be given to maximally safe 
resection followed by adjuvant therapy. 
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Purpose/Objective: Single-fraction carbon-ion radiotherapy 
(CIRT) has been used to treat Stage I non-small cell lung 
cancer (NSCLC) since the dose escalation phase I/II clinical 
trial started in April 2003. In this study the data for patients 
80 year old and over were analyzed to confirm its safety and 
efficacy. 
Materials and Methods: Major patient selection criteria: 1. 
Refused surgery or Inoperable. 2. NSCLC was determined by 
biopsy. 3. Peripheral lung tumors. 4. Tumors were 
measurable T1 or T2 tumors as classified by the UICC sixth 
edition. Custom immobilization devices were used. To 
improve dose distribution, 3 or 4 ports were used with tilt 
angles between plus and minus 20°, as only horizontal and 
vertical carbon-ion beams were available. Each port had an 
even dosage and was irradiated consecutively. The planning 
CT also required tilting the patients. For the treatment of 
planning CIRT, the clinical target volume was defined as gross 
tumor volume plus 10 mm. The planning target volume was 
based on the clinical target volume plus 5 mm in the 
craniocaudal direction. The dose prescription was escalated 
gradually from 28 Grey Equivalent (GyE) to 50 GyE.  
Results: We have treated 218 patients by May 2012. Among 
them, there were 48 males and 22 females, who were 80 
years old and over. The median age was 83 years old (range 
83-89). The median observation term was 42.7 months. 
Biopsies proved 45 adenocarcinomas, 24 squamous cell 
carcinomas, and one non-small cell carcinoma. There were 
39 T1 tumors and 31 T2 tumors. The number of inoperable 
patients was 50. The median treatment dose was 40 GyE 
(range 28-50). 3-year and 5-year overall survival rates were 
72.4% and 39.7%. 3-year and 5-year local control rates were 
88.0% and 85.8%. There was no significant statistical 
difference (p > 0.05) between the disease free survival rates 
for T1 and T2 tumors. There were no grade 3 and over 
adverse effects for the skin and lung during the acute and 
late phases. The grade 2 acute lung effect was observed in 3 
patients whose each prescribed dose was 34, 44, and 48GyE. 
Only one patient had the grade 2 acute and late skin effects, 
whose prescribed dose was 40 GyE.  
Conclusions: We treated 70 patients, who were 80 years old 
and over, with single-fraction CIRT. Single-fraction CIRT 
could be considered safe and efficient treatment options for 
the elderly with stage I peripheral NSCLC. 
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